



# SUDARSHAN PHARMA INDUSTRIES LTD

Head office : 301.Aura Biplax, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail : [compliance@sudarshanpharma.com](mailto:compliance@sudarshanpharma.com) Website : [www.sudarshanpharma.com](http://www.sudarshanpharma.com)

Board Line : + 91-22-42221111 / 42221116 (100 line) CIN : L51496MH2008PLC184997

SPIL/CS/SE/2024-2025/61

Date: 4<sup>th</sup> February 2025

To,  
The Listing Department  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828  
BSE Trading Symbol: SUDARSHAN  
ISIN: INE00TV01023

**Sub: Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 – Proceedings of Extraordinary General Meeting**

Dear Sir / Madam,

We inform you that an Extraordinary General Meeting ('EGM') of the Company was held on Tuesday, 4<sup>th</sup> February, 2025 at 3.00 p.m. through Video Conferencing / Other Audio Visual Means. Pursuant to Regulation 30 and Part A of Schedule III of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we enclose herewith the summary of proceedings of the EGM.

Kindly take the same on record.

Yours truly,

Kindly take it on your records.

For, Sudarshan Pharma Industries Limited

  
Sachin Mehta  
Joint Managing Director &  
Chief Financial Officer



Encl: As above



# SUDARSHAN PHARMA INDUSTRIES LTD

Head office : 301.Aura Biplax, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail : compliance@sudarshanpharma.com Website : www.sudarshanpharma.com

Board Line : + 91-22-42221111 / 42221116 (100 line) CIN : L51496MH2008PLC184997

## Summary of the proceedings of the Extraordinary General Meeting of Sudarshan Pharma Industries Limited

The Extraordinary General Meeting ("EGM") of the members of Sudarshan Pharma Industries Limited (the "Company") was held on Tuesday, 4<sup>th</sup> February, 2025 at 3.00 p.m. through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") to transact the business as set out in the Notice convening EGM dated 10<sup>th</sup> January, 2025.

Mr. Hemal Mehta, Chairman & Managing Director of the Company, chaired the EGM. The Chairman informed that the EGM was held through VC / OAVM in compliance with the circulars issued by the Ministry of Corporate Affairs & Securities and Exchange Board of India. After ascertaining the requisite quorum, the Chairman called the EGM to order.

The Company Secretary introduced all the Directors present, Chief Financial Officer, Company Secretary & Compliance Officer and the Scrutinizer attending the EGM through VC / OAVM.

The Chairman addressed the members, made his opening remarks and reasons for proposing issue and allotment of warrants on a preferential basis to the persons belonging promoters' and non-promoters' category.

The Joint Managing Director & Chief Financial Officer informed the members about the objects of the preferential issue of warrants and the contents of the Corrigendum dated 31<sup>st</sup> January 2025 to Notice of EGM.

The Notice of the EGM and the Corrigendum to the Notice of the EGM were taken as read.

The Chairman informed the members about facility of e-voting provided by the Company to enable the members to cast their votes by electronic means, which shall continue to be available for 15 minutes after the conclusion of the EGM.

The Chairman informed the members that the Company has appointed Mr. Vishal Manseta, Practicing Company Secretary as the Scrutinizer to scrutinize the remote e-voting and e-voting at the EGM in a fair and transparent manner.

The following items of business as per Notice of the EGM were transacted at the EGM:

| Sr. no. | Details of the Agenda   | Resolution required |
|---------|---|---------------------|
| 1       | Issue of 4,30,00,000 Warrants convertible into equity shares on preferential basis to the persons belonging promoters' and non-promoters' category. | Special             |





# SUDARSHAN PHARMA INDUSTRIES LTD

Head office : 301.Aura Biplax, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail : [compliance@sudarshanpharma.com](mailto:compliance@sudarshanpharma.com) Website : [www.sudarshanpharma.com](http://www.sudarshanpharma.com)

Board Line : + 91-22-42221111 / 42221116 (100 line) CIN : L51496MH2008PLC184997

The Chairman further-informed the members that the consolidated results of the voting will be declared within two working days of the conclusion of the EGM upon receipt of the Scrutinizer's Report. The same shall be communicated to BSE Limited and also will be available on the Company's website [www.sudarshanpharma.com](http://www.sudarshanpharma.com)

The Chairman then thanked the members for their continued support and for attending and participating in the EGM. He also thanked the Directors and other panellists for attending the EGM.

After conclusion of the voting process, the EGM ended with a vote of thanks to the Chair at 3:20 p.m.

For, **Sudarshan Pharma Industries Limited**

  
Sachin Mehta  
Joint Managing Director &  
Chief Financial Officer

